Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person sorafenib-resistant FLT3 mutants don't bind sorafenib

Class:IdFailedReaction:9702623
_displayNamesorafenib-resistant FLT3 mutants don't bind sorafenib
_doReleaseTRUE
_timestamp2020-11-06 20:56:37
authored[InstanceEdit:9706566] Rothfels, Karen, 2020-11-06
compartment[Compartment:876] plasma membrane
created[InstanceEdit:9702625] Rothfels, Karen, 2020-10-01
disease[Disease:1500689] cancer
edited[InstanceEdit:9706566] Rothfels, Karen, 2020-11-06
entityFunctionalStatus[EntityFunctionalStatus:9702626] loss_of_function of sorafenib-resistant FLT3 mutants [plasma membrane]
input[DefinedSet:9699530] sorafenib-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[ChemicalDrug:9657029] sorafenib [cytosol]
isChimericFALSE
literatureReference[LiteratureReference:9702875] Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib
[LiteratureReference:9699359] Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
[LiteratureReference:9702954] FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
modified[InstanceEdit:9702941] Rothfels, Karen, 2020-10-02
[InstanceEdit:9703028] Rothfels, Karen, 2020-10-03
[InstanceEdit:9704328] Rothfels, Karen, 2020-10-07
[InstanceEdit:9706570] Rothfels, Karen, 2020-11-06
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
namesorafenib-resistant FLT3 mutants don't bind sorafenib
normalReaction
releaseDate2020-12-08
reviewed[InstanceEdit:9706568] Kazi, Julhash U, 2020-11-06
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9702627] R-HSA-9702623.2
summation[Summation:9702923] The following FLT3 mutants are resistant to sorafenib:
(hasEvent)[Pathway:9702624] sorafenib-resistant FLT3 mutants [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by sorafenib-resistant FLT3 mutants don't bind sorafenib (9702623)
Follow Reactome